<--- Back to Details
First PageDocument Content
Stem cell treatments / Mesenchymal stem cell / Stem cell / Hematopoietic stem cell transplantation / Embryonic stem cell / Geron Corporation / Regenerative medicine / Graft-versus-host disease / Cellular differentiation / Biology / Stem cells / Cell therapy
Date: 2013-12-09 07:07:52
Stem cell treatments
Mesenchymal stem cell
Stem cell
Hematopoietic stem cell transplantation
Embryonic stem cell
Geron Corporation
Regenerative medicine
Graft-versus-host disease
Cellular differentiation
Biology
Stem cells
Cell therapy

Add to Reading List

Source URL: pluristem.com

Download Document from Source Website

File Size: 208,53 KB

Share Document on Facebook

Similar Documents

China Regenerative Medicine International Limited 中國再生醫學國際有限公司 Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立之有限公司 Stock Code 股份代號:8158

DocID: 1vnZo - View Document

[For immediate release] [Press Release] China Regenerative Medicine International Limited (Stock Code: 8158.HK)

DocID: 1vlMf - View Document

Centre for Cell Therapy and Regenerative Medicine 6th Margaret River Region Forum and 9th ASSCR Annual Scientific Meeting Stem Cells: Fundamental Biology and Clinical Translation

DocID: 1v4Rh - View Document

May 24, 2018 CollPlant Reports First Quarter 2018 Financial Results and Provides Business Update NESS ZIONA, Israel, May 24, 2018 /PRNewswire/ -CollPlant (NASDAQ: CLGN) (TASE: CLGN), a regenerative medicine company util

DocID: 1uYu4 - View Document

China Regenerative Medicine International Limited 中國再生醫學國際有限公司 Annual Report 年報

DocID: 1uNPZ - View Document